Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I'm still ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

CRISPR Therapeutics' stock decline is likely ... and Transfusion-Dependent Beta Thalassemia (TDT) early on. Despite this similarity, the two companies are not similarly situated.

CRISPR Therapeutics is a mid-stage biotech specializing ... its CRISPR medicine for sickle cell and beta thalassemia.

CRISPR Therapeutics and Vertex Pharmaceuticals ... to face the toxicity challenges of autologous transplant in SCD and beta-thalassemia patients. With regard to in-vivo therapies, the company ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...